L. Gkekos, A. Johansson, K. Rodriguez-Wallberg, I. Fredriksson, F. Lundberg
{"title":"Obstetric and perinatal outcomes in women with previous breast cancer: a nationwide study of singleton births 1973–2017","authors":"L. Gkekos, A. Johansson, K. Rodriguez-Wallberg, I. Fredriksson, F. Lundberg","doi":"10.1093/hropen/hoae027","DOIUrl":null,"url":null,"abstract":"\n \n \n What are the obstetric and perinatal outcomes in births to breast cancer survivors compared to women without previous breast cancer?\n \n \n \n Women who conceived during the first 2 years following a breast cancer diagnosis had a higher risk for preterm birth, induced delivery and caesarean section, while no increased risks were observed in births conceived later than 2 years after breast cancer diagnosis.\n \n \n \n A recent meta-analysis found higher risks of caesarean section, preterm birth, low birthweight, and small for gestational age in pregnancies among breast cancer survivors. Less is known about rarer outcomes such as pre-eclampsia or congenital malformations.\n \n \n \n We conducted a population-based matched cohort study including all breast cancer survivors who gave birth to singletons 1973–2017 in Sweden, identified through linkage between the Swedish Cancer Register, the Medical Birth Register, and the National Quality Register for Breast Cancer.\n \n \n \n Each birth following breast cancer (n = 926) was matched by maternal age at delivery, parity and calendar year at delivery to 100 births in a comparator cohort of women (n = 92,490). Conditional logistic and multinomial regression models estimated relative risks (RR) with 95% CI. Subgroup analyses by time since diagnosis and type of treatment were performed.\n \n \n \n Previous breast cancer was associated with higher risks of induced delivery (RR; 1.3, 1.0–1.6), very preterm birth (RR; 1.8, 1.1–3.0) and planned preterm birth (RR; 1.6, 1.0–2.4). Women that conceived within 1 year after breast cancer diagnosis had higher risks of caesarean section (RR; 1.7, 1.0–2.7), very preterm birth (RR; 5.3, 1.9–14.8) and low birthweight (RR; 2.7, 1.4–5.2), while the risks of induced delivery (RR; 1.8, 1.1–2.9), moderately preterm birth (RR; 2.1, 1.2–3.7) and planned preterm birth (RR; 2.5, 1.1–5.7) were higher in women that conceived during the second year after diagnosis. Women that conceived later than 2 years after breast cancer diagnosis had similar obstetric risks to their comparators.\n \n \n \n As information on end date of treatment was unavailable, time between the date of diagnosis and conception was used as a proxy, which does not fully capture the effect of time since end of treatment. In addition, treatments and clinical recommendations have changed over the long study period, which may impact childbearing patterns in breast cancer survivors.\n \n \n \n Risks of adverse obstetric outcomes in breast cancer survivors were confined to births conceived within 2 years of diagnosis. As family building holds significance for numerous young breast cancer patients, these findings are particularly important to inform both breast cancer survivors and clinicians about future reproductive outcomes.\n \n \n \n This work was supported by the Swedish Cancer Society (grant number 22-2044 Pj Anna Johansson), Karolinska Institutet Foundations (grant number: 2022-01696 Frida Lundberg, 2022-01559 Anna Johansson), and the Swedish Research Council (grant number: 2021–01657 Anna Johansson). Kenny Rodriguez-Wallberg is supported by grants from the Swedish Cancer society (20 0170 F) and the Radiumhemmets Research Foundations for clinical researchers 2020-2026. The authors declare that they have no conflicts of interests.\n \n \n \n N/A.\n","PeriodicalId":8,"journal":{"name":"ACS Biomaterials Science & Engineering","volume":"84 4","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Biomaterials Science & Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/hropen/hoae027","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
What are the obstetric and perinatal outcomes in births to breast cancer survivors compared to women without previous breast cancer?
Women who conceived during the first 2 years following a breast cancer diagnosis had a higher risk for preterm birth, induced delivery and caesarean section, while no increased risks were observed in births conceived later than 2 years after breast cancer diagnosis.
A recent meta-analysis found higher risks of caesarean section, preterm birth, low birthweight, and small for gestational age in pregnancies among breast cancer survivors. Less is known about rarer outcomes such as pre-eclampsia or congenital malformations.
We conducted a population-based matched cohort study including all breast cancer survivors who gave birth to singletons 1973–2017 in Sweden, identified through linkage between the Swedish Cancer Register, the Medical Birth Register, and the National Quality Register for Breast Cancer.
Each birth following breast cancer (n = 926) was matched by maternal age at delivery, parity and calendar year at delivery to 100 births in a comparator cohort of women (n = 92,490). Conditional logistic and multinomial regression models estimated relative risks (RR) with 95% CI. Subgroup analyses by time since diagnosis and type of treatment were performed.
Previous breast cancer was associated with higher risks of induced delivery (RR; 1.3, 1.0–1.6), very preterm birth (RR; 1.8, 1.1–3.0) and planned preterm birth (RR; 1.6, 1.0–2.4). Women that conceived within 1 year after breast cancer diagnosis had higher risks of caesarean section (RR; 1.7, 1.0–2.7), very preterm birth (RR; 5.3, 1.9–14.8) and low birthweight (RR; 2.7, 1.4–5.2), while the risks of induced delivery (RR; 1.8, 1.1–2.9), moderately preterm birth (RR; 2.1, 1.2–3.7) and planned preterm birth (RR; 2.5, 1.1–5.7) were higher in women that conceived during the second year after diagnosis. Women that conceived later than 2 years after breast cancer diagnosis had similar obstetric risks to their comparators.
As information on end date of treatment was unavailable, time between the date of diagnosis and conception was used as a proxy, which does not fully capture the effect of time since end of treatment. In addition, treatments and clinical recommendations have changed over the long study period, which may impact childbearing patterns in breast cancer survivors.
Risks of adverse obstetric outcomes in breast cancer survivors were confined to births conceived within 2 years of diagnosis. As family building holds significance for numerous young breast cancer patients, these findings are particularly important to inform both breast cancer survivors and clinicians about future reproductive outcomes.
This work was supported by the Swedish Cancer Society (grant number 22-2044 Pj Anna Johansson), Karolinska Institutet Foundations (grant number: 2022-01696 Frida Lundberg, 2022-01559 Anna Johansson), and the Swedish Research Council (grant number: 2021–01657 Anna Johansson). Kenny Rodriguez-Wallberg is supported by grants from the Swedish Cancer society (20 0170 F) and the Radiumhemmets Research Foundations for clinical researchers 2020-2026. The authors declare that they have no conflicts of interests.
N/A.
期刊介绍:
ACS Biomaterials Science & Engineering is the leading journal in the field of biomaterials, serving as an international forum for publishing cutting-edge research and innovative ideas on a broad range of topics:
Applications and Health – implantable tissues and devices, prosthesis, health risks, toxicology
Bio-interactions and Bio-compatibility – material-biology interactions, chemical/morphological/structural communication, mechanobiology, signaling and biological responses, immuno-engineering, calcification, coatings, corrosion and degradation of biomaterials and devices, biophysical regulation of cell functions
Characterization, Synthesis, and Modification – new biomaterials, bioinspired and biomimetic approaches to biomaterials, exploiting structural hierarchy and architectural control, combinatorial strategies for biomaterials discovery, genetic biomaterials design, synthetic biology, new composite systems, bionics, polymer synthesis
Controlled Release and Delivery Systems – biomaterial-based drug and gene delivery, bio-responsive delivery of regulatory molecules, pharmaceutical engineering
Healthcare Advances – clinical translation, regulatory issues, patient safety, emerging trends
Imaging and Diagnostics – imaging agents and probes, theranostics, biosensors, monitoring
Manufacturing and Technology – 3D printing, inks, organ-on-a-chip, bioreactor/perfusion systems, microdevices, BioMEMS, optics and electronics interfaces with biomaterials, systems integration
Modeling and Informatics Tools – scaling methods to guide biomaterial design, predictive algorithms for structure-function, biomechanics, integrating bioinformatics with biomaterials discovery, metabolomics in the context of biomaterials
Tissue Engineering and Regenerative Medicine – basic and applied studies, cell therapies, scaffolds, vascularization, bioartificial organs, transplantation and functionality, cellular agriculture